Apilast contains Apremilast. Apilast uses:
Apilast is indicated for the treatment of adult patients with active psoriatic arthritis and moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
|Therapeutic Class:||Disease-modifying antirheumatic drugs (DMARDs)|
|Manufacturer:||LABAID PHARMACEUTICALS LIMITED|
|Last Updated:||2020-11-19 18:15:00|
Apilast contains Apremilast 10.0 Mg. Apilast doses
The recommended initial dosage titration of Apilast from Day 1 to Day 5 is shown below. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy. Apilast can be administered without regard to meals.
Day 1: 10 mg in morning
Day 2: 10 mg in morning and 10 mg in evening
Day 3: 10 mg in morning and 20 mg in evening
Day 4: 20 mg in morning and 20 mg in evening
Day 5: 20 mg in morning and 30 mg in evening
Day 6 and thereafter: 30 mg twice daily
Dosage adjustment in patients with severe renal impairment
Apilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment. For initial dosage titration, it is recommended that Apilast be titrated using only the morning schedule and the evening doses be skipped.
The most frequently occurring side effects of Apilast are nausea, diarrhea, and headache.
Other less frequent side effects are upper respiratory tract infection, vomiting, nasopharyngitis, abdominal pain, hypersensitivity, gastroesophageal reflux disease, dyspepsia, fatigue, decrease appetite, cough, rash, insomnia.
Apilast is an inhibitor of phosphodiesterase 4 (PDE4) enzyme specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism by which Apilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.
Treatment with Apilast is associated with an increase in adverse reactions of depression. Patients, their caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Apilast if such events occur.
During the controlled period of the studies in psoriatic arthritis, weight decrease between 5%-10% of body weight was reported in 10% of subjects treated with Apilast 30 mg twice daily compared to 3.3% treated with placebo.
Co-administration of strong cytochrome P450 enzyme inducer Rifampin resulted in a reduction of systemic exposure of Apilast.Therefore.the use of cytochrome P450 enzyme inducers (e.g. Rifampin, Phenobarbital,Carbamazepine, Phenytoin) with Apilast is not recommended.
Pregnancy: Pregnancy Category C.
Nursing mothers: It is not known whether Apilast or its metabolites are present in human milk; however Apilast was detected in milk of lactating mice. Caution should be exercised when Apilast is administered to a nursing woman.
Usage in Pediatric Patients
The safety and effectiveness of Apilast in pediatric patients less than18 years of age have not been established.
Apilast is contraindicated in patients with a known hypersensitivity to Apilast or to any of the excipients in the formulation.
Use in Paediatric patient: The safety and effectiveness of Apilast in paediatric patients less than 18 years of age have not been established.
Co-administration of strong cytochrome P450 enzyme inducer, rifampin, resulted in a reduction of systemic exposure of Apilast. Therefore, the use of cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) with Apilast is not recommended.
Store at cool & dry place, protected from light & moisture. Keep the medicine out of the reach of children.
Apilast Tablet price in India 0